

FOR IMMEDIATE RELEASE

March 8, 2018



Listed Company Name: Eisai Co., Ltd.
 Representative: Haruo Naito
 Representative Corporate Officer and CEO
 Securities Code: 4523
 Stock Exchange Listings: First Section of the Tokyo Stock Exchange
 Inquiries: Masatomi Akana
 Vice President, Corporate Affairs
 Phone +81-3-3817-5120

**Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for
 the Fiscal Year Ending March 31, 2018**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “the Company”) announced today that based on the impact of the strategic oncology collaboration for anticancer agent Lenvima announced today as well as recent trends in business results, etc., the Company has revised its consolidated financial forecasts for the fiscal year ending March 31, 2018 (April 1, 2017 to March 31, 2018) previously announced on May 10, 2017, as follows.

1. Revised consolidated financial forecasts for the fiscal year ending March 31, 2018 (April 1, 2017 to March 31, 2018)

(Unit: Millions of yen, unless otherwise noted.)

	Revenue	Operating profit	Profit before income taxes	Profit for the period	Profit attributable to owners of the parent	Basic earnings per share
Previously announced forecast (A) (May 10, 2017)	575,500	60,000	58,300	41,300	39,800	139.17 yen
Currently revised forecast (B)	598,000	82,000	81,200	57,600	55,000	192.22 yen
Change in amount (B - A)	22,500	22,000	22,900	16,300	15,200	
Percentage of change (%)	3.9%	36.7%	39.3%	39.5%	38.2%	
(Reference) Business results for the fiscal year ended March 31, 2017	539,097	59,064	57,668	42,246	39,358	137.63 yen

2. Reason for revision of the consolidated financial forecasts

Due to the recording of contractual upfront payment (¥32,000 million), etc. based on the strategic oncology collaboration for anticancer agent Lenvima, in addition to recent trends in business results, etc., revenue is expected to increase by ¥22,500 million from the previous forecast to ¥598,000 million (up 10.9% year on year) and operating profit is expected to increase from the previous forecast by ¥22,000 million to ¥82,000 million (up 38.8% year on year). Profit for the period attributable to owners of the parent is expected to increase by ¥15,200 million from the previous forecast to ¥55,000 million (up 39.7% year on year). The Company intends to set the dividend for the period (second six-month period ending March 31, 2018) at ¥80 per share, with the forecast for the total dividend for the year remaining unchanged at ¥150 per share (same amount as the previous fiscal year).

Furthermore, the accounting administration for the recording of one-time payments based on the execution of the strategic oncology collaboration is currently being confirmed with the Company's accounting auditor.

*Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of March 8, 2018.
